AK154 + Cadonilimab + Ivonescimab (SMT112 or AK112) Injection + mFOLFORINOX
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreas Cancer
Conditions
Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma
Trial Timeline
Jul 22, 2025 → Nov 6, 2028
NCT ID
NCT06913218About AK154 + Cadonilimab + Ivonescimab (SMT112 or AK112) Injection + mFOLFORINOX
AK154 + Cadonilimab + Ivonescimab (SMT112 or AK112) Injection + mFOLFORINOX is a phase 1 stage product being developed by Akeso for Pancreas Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06913218. Target conditions include Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06913218 | Phase 1 | Recruiting |
Competing Products
20 competing products in Pancreas Cancer